According to the CAPTIVATE Study, fixed-duration ibrutinib plus venetoclax may be beneficial for patients with high-risk chronic lymphocytic leukemia.

Published Date: 09 Jun 2023

Italy: Deep, long-lasting responses and sustained survival seen with fixed-duration ibrutinib plus venetoclax are maintained in high-risk patients.

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

A single-cell analysis reveals a distinctive immunosuppressive tumor microenvironment in kidney cancer brain metastases.

2.

The FDA approves Enhertu for HER2-positive cancers, regardless of tumor type.

3.

Cancer diagnosis does not spur improvements to survivors' diets or eating habits

4.

According to a study by Amrita Hospital in Kochi, cancer mortality is rising among Indian women while declining for men.

5.

A garden can save your life


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot